Clinical Trial Update: A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports the completion of a study evaluating the effects of Boehringer Ingelheim compounds BI 1820237, BI 456906, or their combination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• BI 1820237
• BI 456906

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Obesity | Phase 1 | Status: COMPLETED